iron chelation in mds: still a controversial issue
TRANSCRIPT
E
I
KMIS
iifwtapcln
ticpdmcrlmamctiaIoctpcspf(r
0h
Leukemia Research 38 (2014) 145– 146
Contents lists available at ScienceDirect
Leukemia Research
j o ur nal ho me page: www.elsev ier .com/ locate / leukres
ditorial
ial
ron chelation in MDS: Still a controverseywords:DS
ron chelationurvival
In this issue of Leukemia Research data from a prospective reg-stry concerning the outcomes of lower-risk MDS patients receivingron chelation therapy are presented. The authors analysed datarom 600 lower-risk MDS patients (IPSS low and intermediate-1)ith transfusional iron overload that were enrolled in a prospec-
ive 5-year registry. They compared the clinical outcome 24 monthsfter inclusion into the registry of chelated and nonchelatedatients and found a significantly longer survival especially inonsequently chelated patients as well as a trend towards longereukaemia-free survival and fewer cardiac events as compared toonchelated patients.
In patients with thalassaemia, robust data exist that iron chela-ion leads to a better survival and reduces comorbidities due toron overload like chronic heart failure, diabetes mellitus or liverirrhosis. In MDS, iron overload usually occurs as most of the MDSatients suffer from anaemia and develop transfusion dependencyuring the course of disease. As lower-risk MDS patients have aedian survival of several years and each unit of red blood cells
ontains 200–250 mg iron, especially this patient cohort is at higherisk to develop an iron overload with iron accumulation in heart,iver or endocrine organs. Studies with T2* MRI showed iron accu-
ulation especially in the liver of heavily transfused MDS patientsnd there is evidence that iron chelation can lead to an improve-ent of elevated liver enzymes. It has not been shown that iron
helation can reduce death due to liver failure. MDS is a disease ofhe elderly people and cardiac diseases are a relevant comorbidityn this patient cohort. In a study by Della Porta and colleagues, theuthors presented a comorbidity index for MDS patients (MDS-CI).n their patient cohort, cardiac comorbidities were present in 25%f all patients. Due to the strong prognostic impact, the presence ofardiac comorbidities was counted twice in the score [1]. Iron chela-ion therapy is assumed to reduce cardiac iron overload and preventrogression of cardiac diseases. However, cardiac T2* MRI imagingould not deliver evidence that cardiac iron accumulation has aignificant impact on cardiac comorbidities and outcome of MDSatients in contrast to thalassaemia patients suggesting that other
actors like non-transferrin-bound iron (NTBI) or labile plasma ironLPI) might be important mediators of cardiac dysfunction in low-isk MDS patients. However, in the published study in this issue ofDOI of original article: http://dx.doi.org/10.1016/j.leukres.2013.11.004.
145-2126/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.ttp://dx.doi.org/10.1016/j.leukres.2013.12.004
issue
Leukemia Research as well as in previously published studies, thereis a trend towards fewer cardiac events in chelated patients. There-fore, it will be interesting to see further information on the outcomeof low-risk MDS patients in this registry presented after 5 years offollow up.
Iron chelation found entrance in treatment guidelines for lower-risk MDS patients since several studies showed an improvement ofthe median survival in patients receiving iron chelation therapy.In contrast, data regarding a reduced risk of leukemic progressionor fewer infections in adequately chelated patients are not consis-tent. Several guidelines vary in defining iron overload and whento initiate iron chelation treatment, the recommended time pointwhen to start iron chelation or how to monitor treatment response[2]. The recommendations for iron chelation in low-risk MDS arebased on several studies that all have shortcomings: (a) most ofthem are retrospective analyses, (b) no studies exist comparingdifferent treatment modalities like subcutaneous application ofdeferoxamine or oral application of deferasirox or deferiprone and(c) the decision to start treatment was based on the physicianschoice potentially leading to a bias in patient selection. Anothershortcoming concerns the duration of treatment. As deferoxam-ine has to be administered subcutaneously, compliance of thepatients is pivotal for effective removal of iron. Major side effectsof deferasirox concern nausea, diarrhoea and increase of serumcreatinine. In two prospective trials, the EPIC as well as the US03trial, dropout rates due to adverse events were high with 48.7%and 45%, respectively [3,4]. A prospective, randomised, placebocontrolled study evaluating the effect of deferasirox in heavilytransfused low-risk MDS patients is underway (NCT00940602).The results of this study may help to bring more light into thisfield.
In patients with higher risk MDS, iron chelation can be con-sidered if these patients are candidates for allogeneic stem celltransplantation, as several studies have shown a favourable out-come for patients with normal pretransplantation serum ferritinlevels. The inferior survival of patients with iron overload wasattributable to a significant increase in treatment-related mortality[reviewed in 5].
Although there are approved iron chelation therapies for MDSpatients, future efforts should concentrate on findings bettertreatment options in order to avoid transfusion dependency andconsecutive iron overload.
Conflict of interest statement
The author declares to have no conflict of interest.
1 esearc
R
[
[
[
[
[
46 Editorial / Leukemia R
eferences
1] Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E,et al. Risk stratification on both disease status and extra-hematologic comorbidi-ties in patients with myelodysplastic syndrome. Haematologica 2011;96:441–9.
2] Gattermann N. Overview of guidelines on iron chelation therapy in patientswith myelodysplastic syndromes and transfusional iron overload. Int J Hematol2008;88:24–9.
3] Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, et al. EPIC study investigators deferasirox in iron overloadedpatients with transfusion-dependent myelodysplastic syndromes:results from the large 1-year EPIC study. Leuk Res 2010;34:1143–50.
4] List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N,et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC
transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol2012;30:2134–9.5] Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodys-plastic syndromes: where do we stand? Expert Rev Hematol 2013;6:397–410.
h 38 (2014) 145– 146
Judith Neukirchen ∗
Department of Hematology, Oncology and ClinicalImmunology, Heinrich-Heine-University, Duesseldorf,
Germany
∗ Correspondence to: Department of Hematology,Oncology and Clinical Immunology,
Heinrich-Heine-University, Moorenstr. 5, 40225Düsseldorf, Germany. Tel.: +49 211 8117720;
fax: +49 211 8118853.E-mail address:
24 November 2013
1 December 2013Available online 11 December 2013